NYSE:CLDI Calidi Biotherapeutics (CLDI) Stock Price, News & Analysis $1.16 +0.02 (+1.76%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.12▼$1.1750-Day Range$1.11▼$1.9852-Week Range$1.01▼$90.00Volume76,388 shsAverage Volume152,100 shsMarket Capitalization$58.82 millionP/E RatioN/ADividend YieldN/APrice Target$16.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Calidi Biotherapeutics alerts: Email Address Calidi Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,343.0% Upside$16.67 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.38) to ($0.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.39 out of 5 starsMedical Sector679th out of 910 stocksBiological Products, Except Diagnostic Industry110th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingCalidi Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCalidi Biotherapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Calidi Biotherapeutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for CLDI. Previous Next 0.0 Dividend Strength Dividend YieldCalidi Biotherapeutics does not currently pay a dividend.Dividend GrowthCalidi Biotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLDI. Previous Next 1.1 News and Social Media Coverage Search Interest5 people have searched for CLDI on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows4 people have added Calidi Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Calidi Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders34.50% of the stock of Calidi Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.53% of the stock of Calidi Biotherapeutics is held by institutions.Read more about Calidi Biotherapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Calidi Biotherapeutics are expected to grow in the coming year, from ($4.38) to ($0.59) per share. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.So go here now to read my new report The Big AI Die-Up… while you still can. About Calidi BiotherapeuticsCalidi Biotherapeutics Inc. is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer with a novel stem cell-based therapy. Calidi Biotherapeutics Inc., formerly known as First Light Acquisition Group, is based in SAN DIEGO.Read More CLDI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLDI Stock News HeadlinesAugust 14, 2024 | finanznachrichten.deCalidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial ResultsAugust 13, 2024 | globenewswire.comCalidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial ResultsSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.July 29, 2024 | globenewswire.comCalidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald RigorJuly 18, 2024 | globenewswire.comCalidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology PlatformJuly 16, 2024 | globenewswire.comCalidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory BoardJuly 5, 2024 | businesswire.comCalidi to Effect Reverse Stock SplitJune 11, 2024 | businesswire.comCalidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13September 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.June 10, 2024 | businesswire.comCalidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi's Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid TumorsJune 3, 2024 | businesswire.comCalidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual MeetingMay 31, 2024 | businesswire.comCalidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross ProceedsMay 17, 2024 | finanznachrichten.deCalidi Biotherapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Mone Show on Bloomberg TVMay 15, 2024 | investorplace.comCLDI Stock Earnings: Calidi Biotherapeutics Beats EPS for Q1 2024May 14, 2024 | businesswire.comCalidi Biotherapeutics Reports First Quarter 2024 Operating and Financial ResultsMay 1, 2024 | businesswire.comCalidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual MeetingApril 23, 2024 | finance.yahoo.comJoin Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24April 23, 2024 | businesswire.comJoin Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24See More Headlines Receive CLDI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calidi Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSE:CLDI CUSIPN/A CIK1855485 Webcalidibio.com Phone858-794-9600FaxN/AEmployees38Year FoundedN/APrice Target and Rating Average Stock Price Target$16.67 High Stock Price Target$20.00 Low Stock Price Target$10.00 Potential Upside/Downside+1,343.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,220,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-219.07% Debt Debt-to-Equity RatioN/A Current Ratio0.12 Quick Ratio0.12 Sales & Book Value Annual Sales$50,000.00 Price / Sales1,176.34 Cash FlowN/A Price / Cash FlowN/A Book Value($1.45) per share Price / Book-0.80Miscellaneous Outstanding Shares50,924,000Free Float33,355,000Market Cap$58.82 million OptionableN/A Beta0.60 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key CompetitorsInhibrxNASDAQ:INBXZentalis PharmaceuticalsNASDAQ:ZNTL2seventy bioNASDAQ:TSVTEliem TherapeuticsNASDAQ:ELYMCabaletta BioNASDAQ:CABAView All CompetitorsInstitutional OwnershipDelta Investment Management LLCBought 200,000 shares on 8/15/2024Ownership: 0.413%RS Crum Inc.Bought 252,616 shares on 8/8/2024Ownership: 0.517%CPR Investments Inc.Bought 490,000 shares on 7/19/2024Ownership: 11.002%View All Institutional Transactions CLDI Stock Analysis - Frequently Asked Questions How have CLDI shares performed this year? Calidi Biotherapeutics' stock was trading at $1.9840 at the beginning of 2024. Since then, CLDI shares have decreased by 41.8% and is now trading at $1.1550. View the best growth stocks for 2024 here. How were Calidi Biotherapeutics' earnings last quarter? Calidi Biotherapeutics, Inc. (NYSE:CLDI) released its quarterly earnings results on Tuesday, August, 13th. The company reported ($1.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.43) by $0.03. When did Calidi Biotherapeutics' stock split? Calidi Biotherapeutics shares reverse split before market open on Monday, July 15th 2024. The 1-10 reverse split was announced on Monday, July 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 15th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Calidi Biotherapeutics' major shareholders? Calidi Biotherapeutics' top institutional shareholders include CPR Investments Inc. (11.00%), RS Crum Inc. (0.52%) and Delta Investment Management LLC (0.41%). How do I buy shares of Calidi Biotherapeutics? Shares of CLDI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:CLDI) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLDI Stock Alerts